Cargando…

Quelle chimiothérapie dans les tumeurs phyllodes métastatiques du sein? rapport de cas

Phyllodes tumors (PT) of the breast are rare. They can be benign, borderline or malignant. Malignant forms account for 20-30% of PTs, with distant metastases in 10-26% of cases. Chemotherapy is one of the main therapeutic weapons for metastatic phyllodes tumors (MPTs). We here report four cases of M...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaikai, Imane Ait, Bourhafour, Mouna, Haffadi, Meriem, Bouchbika, Zineb, Benchakroune, Nadia, Jouhadi, Hassan, Tawfiq, Nezha, Sahraoui, Souha, Benider, Abdellatif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The African Field Epidemiology Network 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643797/
https://www.ncbi.nlm.nih.gov/pubmed/36415336
http://dx.doi.org/10.11604/pamj.2022.42.293.20377
_version_ 1784826597578113024
author Kaikai, Imane Ait
Bourhafour, Mouna
Haffadi, Meriem
Bouchbika, Zineb
Benchakroune, Nadia
Jouhadi, Hassan
Tawfiq, Nezha
Sahraoui, Souha
Benider, Abdellatif
author_facet Kaikai, Imane Ait
Bourhafour, Mouna
Haffadi, Meriem
Bouchbika, Zineb
Benchakroune, Nadia
Jouhadi, Hassan
Tawfiq, Nezha
Sahraoui, Souha
Benider, Abdellatif
author_sort Kaikai, Imane Ait
collection PubMed
description Phyllodes tumors (PT) of the breast are rare. They can be benign, borderline or malignant. Malignant forms account for 20-30% of PTs, with distant metastases in 10-26% of cases. Chemotherapy is one of the main therapeutic weapons for metastatic phyllodes tumors (MPTs). We here report four cases of MPTs of the breast managed at The Mohammed VI Center For Cancers Treatment in Casablanca from January 2015 to December 2017. The average age of patients ranged from 25 to 45 years. The mode of revelation was represented, in the majority of cases, by the occurrence of a huge breast mass and in all patients the histological diagnosis was based on the examination of mastectomy specimen. Three patients had lung metastases, two had axillary lymph-node metastases, two had bone metastases and only one had liver metastases. All patients received chemotherapy. Doxorubicin monotherapy and doxorubicin-ifosfamide (AI) were used. Only one patient had a very favorable outcome, with radiologic complete response after 3 AI regimens. MPTs of the breast have a poor prognosis. The role of systemic chemotherapy is to be defined, especially since there are no data available on optimal chemotherapy regimen.
format Online
Article
Text
id pubmed-9643797
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The African Field Epidemiology Network
record_format MEDLINE/PubMed
spelling pubmed-96437972022-11-21 Quelle chimiothérapie dans les tumeurs phyllodes métastatiques du sein? rapport de cas Kaikai, Imane Ait Bourhafour, Mouna Haffadi, Meriem Bouchbika, Zineb Benchakroune, Nadia Jouhadi, Hassan Tawfiq, Nezha Sahraoui, Souha Benider, Abdellatif Pan Afr Med J Case Report Phyllodes tumors (PT) of the breast are rare. They can be benign, borderline or malignant. Malignant forms account for 20-30% of PTs, with distant metastases in 10-26% of cases. Chemotherapy is one of the main therapeutic weapons for metastatic phyllodes tumors (MPTs). We here report four cases of MPTs of the breast managed at The Mohammed VI Center For Cancers Treatment in Casablanca from January 2015 to December 2017. The average age of patients ranged from 25 to 45 years. The mode of revelation was represented, in the majority of cases, by the occurrence of a huge breast mass and in all patients the histological diagnosis was based on the examination of mastectomy specimen. Three patients had lung metastases, two had axillary lymph-node metastases, two had bone metastases and only one had liver metastases. All patients received chemotherapy. Doxorubicin monotherapy and doxorubicin-ifosfamide (AI) were used. Only one patient had a very favorable outcome, with radiologic complete response after 3 AI regimens. MPTs of the breast have a poor prognosis. The role of systemic chemotherapy is to be defined, especially since there are no data available on optimal chemotherapy regimen. The African Field Epidemiology Network 2022-08-18 /pmc/articles/PMC9643797/ /pubmed/36415336 http://dx.doi.org/10.11604/pamj.2022.42.293.20377 Text en Copyright: Imane Ait Kaikai et al. https://creativecommons.org/licenses/by/4.0/The Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Kaikai, Imane Ait
Bourhafour, Mouna
Haffadi, Meriem
Bouchbika, Zineb
Benchakroune, Nadia
Jouhadi, Hassan
Tawfiq, Nezha
Sahraoui, Souha
Benider, Abdellatif
Quelle chimiothérapie dans les tumeurs phyllodes métastatiques du sein? rapport de cas
title Quelle chimiothérapie dans les tumeurs phyllodes métastatiques du sein? rapport de cas
title_full Quelle chimiothérapie dans les tumeurs phyllodes métastatiques du sein? rapport de cas
title_fullStr Quelle chimiothérapie dans les tumeurs phyllodes métastatiques du sein? rapport de cas
title_full_unstemmed Quelle chimiothérapie dans les tumeurs phyllodes métastatiques du sein? rapport de cas
title_short Quelle chimiothérapie dans les tumeurs phyllodes métastatiques du sein? rapport de cas
title_sort quelle chimiothérapie dans les tumeurs phyllodes métastatiques du sein? rapport de cas
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643797/
https://www.ncbi.nlm.nih.gov/pubmed/36415336
http://dx.doi.org/10.11604/pamj.2022.42.293.20377
work_keys_str_mv AT kaikaiimaneait quellechimiotherapiedanslestumeursphyllodesmetastatiquesduseinrapportdecas
AT bourhafourmouna quellechimiotherapiedanslestumeursphyllodesmetastatiquesduseinrapportdecas
AT haffadimeriem quellechimiotherapiedanslestumeursphyllodesmetastatiquesduseinrapportdecas
AT bouchbikazineb quellechimiotherapiedanslestumeursphyllodesmetastatiquesduseinrapportdecas
AT benchakrounenadia quellechimiotherapiedanslestumeursphyllodesmetastatiquesduseinrapportdecas
AT jouhadihassan quellechimiotherapiedanslestumeursphyllodesmetastatiquesduseinrapportdecas
AT tawfiqnezha quellechimiotherapiedanslestumeursphyllodesmetastatiquesduseinrapportdecas
AT sahraouisouha quellechimiotherapiedanslestumeursphyllodesmetastatiquesduseinrapportdecas
AT beniderabdellatif quellechimiotherapiedanslestumeursphyllodesmetastatiquesduseinrapportdecas